Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIO-01 in Recurrent Solid Tumors
NCT06257758Phase 2Terminated
- Sponsor
- Valerio Therapeutics
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VIO-01 in solid tumor (advanced stage), breast cancer, ovarian cancer, prostate cancer (PCa), sponsored by Valerio Therapeutics. Started Jan 2024; status: terminated.
02
Drugs
VIO-01
03
Conditions
solid tumor (advanced stage)breast cancerovarian cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT06257758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06257758.